WO2004016646A3 - Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk) - Google Patents

Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk) Download PDF

Info

Publication number
WO2004016646A3
WO2004016646A3 PCT/EP2003/008901 EP0308901W WO2004016646A3 WO 2004016646 A3 WO2004016646 A3 WO 2004016646A3 EP 0308901 W EP0308901 W EP 0308901W WO 2004016646 A3 WO2004016646 A3 WO 2004016646A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
pyruvate kinase
tumour specific
peptide modulators
kinase subtype
Prior art date
Application number
PCT/EP2003/008901
Other languages
French (fr)
Other versions
WO2004016646A2 (en
Inventor
Gilles Spoden
Werner Paul Zwerschke
Hendrik Pidder Jansen-Duerr
Barbara Fitzky
Original Assignee
Amynon Bio Tech Gmbh
Gilles Spoden
Werner Paul Zwerschke
Hendrik Pidder Jansen-Duerr
Barbara Fitzky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amynon Bio Tech Gmbh, Gilles Spoden, Werner Paul Zwerschke, Hendrik Pidder Jansen-Duerr, Barbara Fitzky filed Critical Amynon Bio Tech Gmbh
Priority to AU2003266272A priority Critical patent/AU2003266272A1/en
Publication of WO2004016646A2 publication Critical patent/WO2004016646A2/en
Publication of WO2004016646A3 publication Critical patent/WO2004016646A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/0104—Pyruvate kinase (2.7.1.40)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to (a) peptide(s) capable of specifically interacting with pyruvate kinase subtype M2 (M2-PK), wherein said peptide(s) comprise(s) (an) amino acid sequence(s) as disclosed herein. Furthermore, the invention provides for nucleic acid molecule(s) comprising nucleotide sequence(s) encoding said peptide(s), for vectors comprising said nucleic acid molecule(s). In addition, pharmaceutical and diagnostic compositions are disclosed which comprise the peptide(s) of the invention. The invention also relates to specific uses of the peptide(s) of the invention in preparation of pharmaceutical compositions for the treatment or prevention of, inter alia, proliferative and/or tumorous diseases.
PCT/EP2003/008901 2002-08-12 2003-08-11 Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk) WO2004016646A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003266272A AU2003266272A1 (en) 2002-08-12 2003-08-11 Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02017791 2002-08-12
EP02017791.1 2002-08-12

Publications (2)

Publication Number Publication Date
WO2004016646A2 WO2004016646A2 (en) 2004-02-26
WO2004016646A3 true WO2004016646A3 (en) 2004-12-16

Family

ID=31725344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008901 WO2004016646A2 (en) 2002-08-12 2003-08-11 Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)

Country Status (2)

Country Link
AU (1) AU2003266272A1 (en)
WO (1) WO2004016646A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042867A2 (en) * 2008-10-09 2010-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
US20180072812A1 (en) * 2015-02-26 2018-03-15 Proda Biotech Llc Molecules disrupting pyruvate kinase m2 and integrin interaction and uses thereof
JP2021519073A (en) * 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド Regulation of lactogenic activity in mammalian cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3838900A1 (en) * 1988-11-17 1990-05-23 Scheefers Borchel Ursula PYRUVATKINASE-ISOENZYM TYPE M2 (TUMOR M2-PK) SPECIFIC ANTIBODIES / METHOD FOR THE PRODUCTION AND USE THEREOF
WO1998002539A1 (en) * 1996-07-15 1998-01-22 The Regents Of The University Of California GENES FROM 20q13 AMPLICON AND THEIR USES
DE10029131A1 (en) * 2000-06-14 2002-01-03 Ulf R Rapp New nucleic acid encoding protein kinase of the mitogenic signaling pathway, useful for identifying cytostatic agents, includes the sequence of a glycolytic enzyme binding site
US6358683B1 (en) * 1999-06-03 2002-03-19 The Regents Of The University Of California Blood-based assays for breast cancer
WO2002072077A2 (en) * 2001-03-13 2002-09-19 Schebo Biotech Ag Use of amino acids, amino acid analogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression
WO2002095063A1 (en) * 2001-05-23 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pyruvate-kinase as a novel target molecule

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3838900A1 (en) * 1988-11-17 1990-05-23 Scheefers Borchel Ursula PYRUVATKINASE-ISOENZYM TYPE M2 (TUMOR M2-PK) SPECIFIC ANTIBODIES / METHOD FOR THE PRODUCTION AND USE THEREOF
WO1998002539A1 (en) * 1996-07-15 1998-01-22 The Regents Of The University Of California GENES FROM 20q13 AMPLICON AND THEIR USES
US6358683B1 (en) * 1999-06-03 2002-03-19 The Regents Of The University Of California Blood-based assays for breast cancer
DE10029131A1 (en) * 2000-06-14 2002-01-03 Ulf R Rapp New nucleic acid encoding protein kinase of the mitogenic signaling pathway, useful for identifying cytostatic agents, includes the sequence of a glycolytic enzyme binding site
WO2002072077A2 (en) * 2001-03-13 2002-09-19 Schebo Biotech Ag Use of amino acids, amino acid analogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression
WO2002095063A1 (en) * 2001-05-23 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pyruvate-kinase as a novel target molecule

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLAS P ET AL: "GENETIC SELECTION OF PEPTIDE APTAMERS THAT RECOGNIZE AND INHIBIT CYCLIN-DEPENDENT KINASE 2", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 380, 11 April 1996 (1996-04-11), pages 548 - 550, XP000904376, ISSN: 0028-0836 *
DATABASE EMBL [online] EMBL; 17 October 2001 (2001-10-17), PENN SG. ET AL: "Peptide #9124 encoded by probe for measuring placental gene expression", XP002282731, retrieved from EBI Database accession no. AAM35087 *
DATABASE EMBL [online] EMBL; 5 November 2001 (2001-11-05), PENN SG. ET AL.: "Human brain expressed single exon probe encoded protein SEQ ID NO: 34272.", XP002282732, retrieved from EBI Database accession no. AAM62167 *
MAZUREK SYBILLE ET AL: "Metabolic cooperation between different oncogenes during cell transformation: Interaction between activated ras and HPV-16 E7", ONCOGENE, vol. 20, no. 47, 18 October 2001 (2001-10-18), pages 6891 - 6898, XP002270961, ISSN: 0950-9232 *
ZWERSCHKE W ET AL: "IDENTIFICATION OF DOMAINS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION AND PROTEIN DIMERIZATION IN THE HUMAN PAPILLOMAVIRUS TYPE-16 E7 PROTEIN", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 12, 4 January 1996 (1996-01-04), pages 213 - 220, XP002060202, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
AU2003266272A1 (en) 2004-03-03
WO2004016646A2 (en) 2004-02-26
AU2003266272A8 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
UA91815C2 (en) Isolated antibody that specifically binds to gdf-8 and use thereof
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2001001748A3 (en) Peptide compounds that bind her2
MX2012008999A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340015B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
WO2007009894A3 (en) Peptides for use in the treatment of obesity
MXPA04008077A (en) ANTI-Abeta ANTIBODIES AND THEIR USE.
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2005003296A3 (en) Albumin fusion proteins
WO2006048450A3 (en) Peptides for use in the treating obesity
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2008133208A1 (en) Method for enhancing immune response with peptide
WO2007110709A8 (en) Formulations of tipifarnib for intravenous administration
WO2006000213A3 (en) Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
CA2634902A1 (en) Anticancer agent comprising a peptide
WO2004087766A3 (en) Peptabody for cancer treatment
WO2006130639A3 (en) Novel glutamic acid decarboxylase (gad) chimera and methods of use
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2004016646A3 (en) Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)
WO2006018431A3 (en) Peptides for the treatment of herpes virus infections
WO2004085461A3 (en) Tumour-associated peptides binding to mhc molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP